← Back to Search

Monoclonal Antibodies

Regeneron Casirivimab + Imdevimab for Coronavirus (OPTIMISE-C19 Trial)

Phase 4
Waitlist Available
Led By David Huang, MD
Research Sponsored by University of Pittsburgh Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
COVID-19 positive patients
Eligible for mAB under FDA EUA
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of study
Awards & highlights

OPTIMISE-C19 Trial Summary

This study is evaluating whether multiple monoclonal antibodies may be effective in treating Ebola.

Eligible Conditions
  • Coronavirus

OPTIMISE-C19 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

OPTIMISE-C19 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days after initial participation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days after initial participation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hospital-free Days
Secondary outcome measures
All-cause Mortality at 28 Days
Detection of SARS-CoV-2 Variants Through Next-generation Sequencing
Duration of SAR-CoV-2 Infectivity
+7 more

OPTIMISE-C19 Trial Design

5Treatment groups
Experimental Treatment
Group I: SotrovimabExperimental Treatment1 Intervention
The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
Group II: Regeneron Casirivimab + ImdevimabExperimental Treatment1 Intervention
The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset.
Group III: Lilly Bamlanivimab + EtesevimabExperimental Treatment1 Intervention
The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset.
Group IV: Lilly BamlanivimabExperimental Treatment1 Intervention
The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset.
Group V: BebtelovimabExperimental Treatment1 Intervention
The monoclonal antibody of bebtelovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sotrovimab
2022
Completed Phase 3
~540
Bebtelovimab
2020
Completed Phase 2
~1760

Find a Location

Who is running the clinical trial?

University of Pittsburgh Medical CenterLead Sponsor
70 Previous Clinical Trials
71,679 Total Patients Enrolled
David T HuangLead Sponsor
Erin McCrearyLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1143 spots leftby Mar 2025